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valuations were derived from the EQ-VAS. Population 
valuations were derived from the EQ-5D-3L using a Dutch 
VAS-based tariff. The difference between patient and popu-
lation valuations was assessed using t tests. An OLS linear 
regression model was constructed to explore how various 
aspects of health-related quality of life as measured by the 
ED-5D-3L impact non-specific LBP patient valuations.
Results Non-specific LBP patients valued their health 
states 0.098 (95% CI 0.082–0.115) points higher than the 
general population. Only 22.2% of the variance in patient 
valuations was explained by the patients’ EQ-5D-3L health 
states (R2 = 0.222). Non-specific LBP patients gave the 
most weight to the anxiety/depression dimension.
Conclusions This study demonstrated that non-specific 
LBP patients value their health states higher than members 
of the general population and that the choice of valuation 
method could have important implications for cost-effec-
tiveness analyses and thus for clinical practice.
Keywords Low back pain · Health state valuation · Cost-
effectiveness analysis · EQ-5D-3L · EQ-VAS
Introduction
The high disease and economic burden of low back pain 
(LBP) has led to the development and evaluation of a broad 
range of LBP treatments [1–3]. Cost-effectiveness analyses 
can support decision-makers on the allocation of scarce 
resources by comparing alternative (LBP) treatments in 
terms of both their costs and effects [4]. Quality-adjusted 
life years (QALYs) are often used as an effect measure in 
cost-effectiveness analyses. QALYs capture the two most 
important features of a treatment in one metric; i.e., its 
effect on quantity of life and its effect on quality of life. 
Abstract 
Purpose The purpose of this study was twofold: (1) to 
compare non-specific low back pain (LBP) patients’ health 
state valuations with those of the general population, and 
(2) to explore how aspects of health-related quality of life 
as measured by the EQ-5D-3L impact non-specific LBP 
patient valuations.
Methods Data were used of a randomized controlled 
trial, including 483 non-specific LBP patients. Out-
comes included the EQ-VAS and the EQ-5D-3L. Patient 
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For estimating a treatment’s effect on quality of life, health 
state valuations are used. Health state valuations are basi-
cally preference weights, indicating a person’s preference 
for a health state on a scale anchored at 0 (equal to death) 
and 1 (equal to full health) [4, 5].
Even though the valuation of health states is essential for 
cost-effectiveness analyses, debate still exists as to whom 
should value health states [4–6]. That is, whether health 
states should be valued by patients themselves or by mem-
bers of the general population. In most studies, members 
of the general population are used [6, 7]. Others argue that 
patient valuations should be used [6, 8].
To our knowledge, Mann et al. have been the only ones 
to compare patient and population valuations among non-
specific LBP patients (i.e., LBP with no specific cause, 
such as a tumor, infection, fracture, and herniated disk) [9]. 
They found patient valuations to be lower than population 
valuations, indicating that non-specific LBP patients per-
ceive their health states to be worse than the general pop-
ulation does. This, however, contrasts the results of other 
studies in this area, most of which found patient valuations 
to be higher than population valuations, or to be similar 
[10, 11]. Therefore, the aim of the current study was two-
fold: (1) to compare non-specific LBP patients’ health state 
valuations with those of the general population and (2) to 
explore how various aspects of health-related quality of life 




Data were used of a randomized controlled trial (RCT) 
assessing the (cost-)effectiveness of an active implementa-
tion strategy for the Dutch Physical Therapy guidelines for 
LBP patients [12]. The study was approved by the Medical 
Ethics Committee of the VU University Medical Centre, 
Amsterdam, the Netherlands.
Study population
The study population consisted of 483 Dutch non-specific 
LBP patients. They were referred by their general practi-
tioner to a physical therapist to receive treatment for a new 
episode of non-specific LBP [12]. The participants’ base-
line characteristics are provided in Table 1.
Outcome measures
Outcome measures included the EQ-VAS and the EQ-
5D-3L. In the RCT, both were measured at baseline, 6, 12, 
26, and 52 weeks. For this study, we solely used baseline 
data, where EQ-VAS and EQ-5D-3L data were complete.
EQ‑VAS
The EQ-VAS is a visual analogue scale, ranging from 
‘worst imaginable health state’  (0) to ‘best imaginable 
health state’ (100).
EQ‑5D‑3L
The EQ-5D-3L consists of five health dimensions: (1) 
mobility; (2) self-care; (3) usual activities; (4) pain/discom-
fort; and (5) anxiety/depression. Each dimension contains 
three severity levels: (1) no problems; (2) some or moder-
ate problems; and (3) severe problems. For each dimension, 
patients are asked to report the level that best describes 
their current health state. The five health dimensions com-
bined with the three severity levels result in 243 possible 
health states, ranging from 11111 (no problems on all 
dimensions) to 33333 (severe problems on all dimensions) 
[13].
Estimating patient valuations
The participants’ EQ-VAS scores were transformed into 
health state values, where 0 represents death and 1 repre-
sents full health. Note that simply dividing EQ-VAS scores 
by 100 will not achieve this, as an EQ-VAS score of 0 is 
not necessarily equivalent to death and an EQ-VAS score of 
Table 1  Baseline characteristics of the study population
SD standard deviation, n number, LBP low back pain
Baseline characteristics Low back 
pain patients 
(n = 483)
Age [mean (SD)] 44.4 (14.0)
Gender [n (%); female] 250 (51.8)
Pain [mean (SD); Numerical Rating Scale 0–10] 6.3 (2.0)
Prior episode of LBP [n (%); yes] 351 (72.7)
Duration current LBP episode [n (%)]
 0–6 weeks (acute non 241 (49.9)
 6–12 weeks (sub 85 (17.6)
 >12 weeks (chronic non-specific LBP) 151 (31.3)
 Unknown 6 (1.2)




 Not applicable 131 (27.1)
 Unknown 5 (1.0)
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100 is not necessarily equivalent to full health [14]. There-
fore, EQ-VAS scores were transformed into health state 
values using the following formula (further referred to as 
patient valuations):
where  VASdeath is assumed to equal 0.085 and  VAS11111 
0.987 [15].
Estimating population valuations
The participants’ EQ-5D-3L health states were converted 
into health state values using a Dutch VAS-based tar-
iff (further referred to as population valuations) [14]. The 
Dutch VAS-based tariff was developed using a sample of 
212 adults that were representative of the Dutch population 
with regard to age, gender, and perceived health. Within 
this study, participants were asked to rate a number of EQ-
5D-3L health states on a VAS scale. Using these data, the 
authors developed an algorithm (i.e., tariff) that can be used 
to convert EQ-5D-3L health states into health state values 
that are based on the preferences of the general population 
[14].
Statistical analyses
Comparing non‑specific LBP patient valuations 
and population valuations.
Non-specific LBP patient valuations and population valu-
ations were compared using a paired t test. To explore 
whether the difference between patient and population val-
uations systematically increased with LBP duration, sub-
group analyses were performed among acute (LBP for 0–6 
weeks), sub-acute (LBP for 6–12 weeks), and chronic LBP 
patients (LBP for >12 weeks).
Relationship between EQ‑5D‑3L health states 
and non‑specific LBP patient valuations.
To explore how various aspects of health-related quality 
of life as measured by the EQ-5D-3L impact non-specific 
LBP patient valuations, an ordinary least squares (OLS) 
linear regression model was constructed with 1 minus the 
participants’ patient valuations as dependent variable and 
11 independent variables describing their EQ-5D-3L health 
states. Ten out of the 11 independent variables comprised 
dummy variables for the EQ-5D-3L dimensions, with the 
level reflecting “no problems” as reference. In line with the 
previous models, an N3 dummy variable was added to the 
Patient valuations = (VASscore∕100) − VASdeath)∕
(VAS11111 − VASdeath),
model, indicating whether at least one dimension was at 
level 3 (i.e., 11th independent variable) [14]. The model’s 
 R2 was estimated and the coefficients derived from the OLS 




An overview of the frequencies with which the three lev-
els of the EQ-5D-3L dimensions were scored is provided 
in Table  2. Most notably, patients hardly scored level 3 
(‘severe problems’). An overview of all occurring EQ-
5D-3L health states and their frequencies can be found in 
Appendix 1.
Comparing non-specific LBP patient valuations 
and population valuations
The participants’ patient valuations (mean = 0.731; 
SD = 0.172) were statistically significantly higher than 
their population valuations (mean = 0.632; SD = 0.167) 
(β = 0.098; 95% CI 0.082–0.115). Participants with acute, 
sub-acute, and chronic non-specific LBP valued their 
health state significantly higher compared with mem-
bers of the general population. The discrepancy between 
patient and population valuations was most pronounced 
among participants with acute non-specific LBP, and 
least pronounced among participants with sub-acute non-
specific LBP (Table 3).
Relationship between EQ-5D-3L health states 
and non-specific LBP patient valuations
Coefficients for the usual activities, pain/discomfort, and 
anxiety/depression dimensions of the EQ-5D-3L were in 
the expected direction with larger decrements associated 















Level 1 52.4 75.6 22.2 11.4 77.6
Level 2 47.2 24.2 69.8 79.5 21.3
Level 3 0.4 0.1 8.0 9.1 1.1
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with the higher severity levels, whereas those of the 
mobility and self-care dimension were not. Five coeffi-
cients were statistically significant; all others were not. 
The model’s R2 was 0.222 (Table 4).
As very few participants scored level three on the mobil-
ity and self-care dimension (Table  2), the level 3 coef-
ficients of the mobility and self-care dimension were not 
compared with those of the general population. When com-
paring all other coefficients, the usual activities and anxi-
ety/depression coefficients were similar in both models, 
whereas the decrements for mobility (only level 2), self-
care (only level 2), and pain/discomfort were smaller in the 




Comparing non‑specific LBP patient valuations 
and population valuations
This study indicated that non-specific LBP patients value 
their health states on average 0.098 (95% CI 0.082–0.115) 
points higher than members of the general population. This 
difference exceeds the minimal clinically important differ-
ence for the EQ-5D-3L (i.e., 0.05–0.08) [16] and is in line 
with the most recent review on this topic [11]. It should be 
noted, however, that non-specific LBP patients were not 
included in this review. In addition, the results of the only 
Table 3  mean patient valuations, mean population valuations, and mean differences between patient and population valuations





Mean difference between 
patient and population valu-
ations
Mean (95% CI)
All non-specific LBP patients (n = 483) 0.731 (0.172) 0.632 (0.167) 0.098 (0.082 to 0.115)
Acute non-specific LBP patients (n = 241) 0.724 (0.164) 0.608 (0.170) 0.115 (0.092 to 0.139)
Sub-acute non-specific LBP patients (n = 85) 0.718 (0.199) 0.656 (0.170) 0.059 (0.020 to 0.097)
Chronic non-specific LBP patients (n = 151) 0.748 (0.155) 0.656 (0.155) 0.092 (0.064 to 0.120)
Table 4  General population and non-specific low back pain patient coefficients for the EQ-5D-3L dimensions
R2 R-squared, n number
*Note that both models were constructed with 1 minus the participants’ patient valuations (derived using the EQ-VAS) as dependent variable 







Constant Subtract if at least one level is at 2 or 3 0.173 0.146 (0.103 to 0.190)
Mobility (2) Subtract if mobility is at level 2 0.101 0.039 (0.008 to 0.069)
Mobility (3) Subtract if mobility is at level 3 0.227 0.022 (−0.295 to 0.340)
Self-care (2) Subtract if self-care is at level 2 0.081 0.017 (−0.018 to 0.051)
Self-care (3) Subtract if self-care is at level 3 0.090 −0.308 (−0.765 to 0.150)
Usual activities (2) Subtract if usual activities is at level 2 0.040 0.038 (0.001 to 0.074)
Usual activities (3) Subtract if usual activities is at level 3 0.080 0.088 (−0.016 to 0.192)
Pain / discomfort (2) Subtract if pain/discomfort is at level 2 0.065 0.038 (−0.006 to 0.083)
Pain / discomfort (3) Subtract if pain/discomfort is at level 3 0.173 0.074 (−0.036 to 0.184)
Anxiety / depression (2) Subtract if anxiety/depression is at level 2 0.054 0.085 (0.051 to 0.119)
Anxiety / depression (3) Subtract if anxiety/depression is at level 3 0.155 0.143 (0.004 to 0.281)
Any dimension at level 3 Subtract if any dimension is at level 3 0.142 0.073 (−0.037 to 0.184)
R2 0.384 0.222
n 298 483
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study that did include non-specific LBP patients contrast 
those of the present study [10]. The latter may be due to 
the absence of acute non-specific LBP patients in the previ-
ous study [10] as well as differences between both studies 
with regard to the percentage of female participants (i.e., 
53% in the present study versus 61% in the previous one) 
as well as the percentage of participants that experienced a 
prior LBP episode (i.e., 75 versus 84%) [10]. Furthermore, 
even though clinical experience suggests that people adapt 
to longer term ill health [4], no evidence was found in the 
present study to support this proposition. That is, the dif-
ference between patient and population valuations did no 
systematically increase with LBP duration.
Relationship between EQ‑5D‑3L health states 
and non‑specific LBP patient valuations
Only 22.2% of the variance in the participants’ patient 
valuations was explained by their EQ-5D-3L health states. 
This indicates that the EQ-5D-3L health state descriptions 
may be too coarse to comprehensively describe non-spe-
cific LBP patient health states and thus their self-perceived 
health-related quality of life [17]. The recently developed 
five-level version of the EQ-5D (i.e., EQ-5D-5L) may 
provide a possible means for improvement, but further 
research is needed to establish this. It might also be, how-
ever, that health dimensions other than those covered by the 
EQ-5D-3L play an important role in predicting non-specific 
LBP patients’ self-perceived health-related quality of life 
(e.g., vitality, well-being, and role functioning). As existing 
health state questionnaires (e.g., EQ-5D, SF-6D, HUI) vary 
widely in terms of health dimensions [4, 6], future research 
is warranted to explore which of them is most suitable for 
LBP research and clinical practice, and/or whether an LBP-
specific health state questionnaire ought to be developed. 
Results also indicated that non-specific LBP patients gave 
the most weight to the anxiety/depression dimension of 
the EQ-5D-3L, and it seems that mobility, self-care and 
pain/discomfort were less important for non-specific LBP 
patients than for members of the general population. Both 
findings are in line with those of Mann et  al. who attrib-
uted them to the possibility that non-specific LBP patients 
adapt to some extent to problems with mobility, self-care 
and pain/discomfort, but less to mental health problems [9].
Strengths and limitations
The main strength of the present study is that it was the 
first to compare patient and population health state valu-
ations among all subgroups of non-specific LBP patients. 
Herewith, the present study provides valuable input into the 
discussion of how to value health-related quality of life in 
cost-effectiveness analyses in general and in LBP research 
in particular.
The present study also has some limitations. First, the 
study population consisted of non-specific LBP patients 
who participated in a Dutch RCT. Consequently, it is 
unknown to what extent the present findings are generaliz-
able to Dutch non-specific LBP patients in general, to those 
living outside the Netherlands, and to those suffering from 
LBP with a specific cause. Second, the present study relied 
heavily on VAS valuations, which are generally considered 
to be inferior to other health state valuation methods, such 
as the Time Tradeoff (TTO) and the Standard Gamble (SG) 
[6, 18]. Future research is, therefore, needed to explore 
whether the present findings would hold when using the 
TTO and the SG.
Implications for research and practice
The present findings provide further evidence that it can 
make a difference whose health state valuations are used. 
That is, non-specific LBP patient valuations were statisti-
cally significantly and clinically meaningfully higher than 
population valuations. As a consequence, the incremen-
tal gain from reducing the participants’ complaints and 
restoring them to full health could have been 1.4 times 
larger when population instead of patient valuations were 
used [i.e., (1 − 0.731)/(1 − 0.632)]. This indicates that the 
choice of valuation method could have a substantial effect 
on the results of cost-effectiveness analyses [18]. There-
fore, researchers are encouraged to explore the implications 
of the choice of valuation method on the outcome of their 
cost-effectiveness analysis using a sensitivity analysis. Sec-
ond, the finding that only 22.2% of the variance in patient 
valuations was explained by the participants’ EQ-5D-3L 
health states indicates that the EQ-5D-3L might not be the 
optimal measure for estimating non-specific LBP patients’ 
self-perceived health-related quality of life. Therefore, fur-
ther research is needed to explore which existing health 
state questionnaire (e.g., EQ-5D-3L, EQ-5D-5L, SF-6D, 
and HUI) is most suitable for estimating self-perceived 
health-related quality of life among non-specific LBP 
patients and/or whether an LBP-specific health state ques-
tionnaire ought to be developed.
Conclusion
This study demonstrated that non-specific LBP patients 
value their health state better than members of the gen-
eral population and that the choice of valuation method 
could have important implications for cost-effectiveness 
1632 Qual Life Res (2017) 26:1627–1633
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analyses and thus for healthcare decision making and clini-
cal practice.
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Appendix 1: Frequencies and percentages 
with which the various EQ-5D-3L health states 
were scored
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